The U.S. Food and Drug Administration approved Acadia Pharmaceuticals Inc’s drug for the treatment of Rett syndrome, a genetic brain disorder, the company said on Friday, making it the first approved drug for the condition. The U.S. health regulator’s decision allows use of the trofinetide, to be sold under the brand name Daybue…
Read More
About The Author
